Moderna jumps 11% in two sessions as whale short nears liquidation before cancer data release

Moderna jumps 11% in two sessions as whale short nears liquidation before cancer data release

N
News Editor
2026-10-21 07:30:47
Moderna shares extended their rebound ahead of a closely watched cancer therapy data presentation, rising 4.07% and 6.69% over the past two U.S. trading sessions for a combined gain of about 11.04%. The stock last closed at $242.08 and touched an intraday high of $243.98, while the corresponding Hyperliquid contract traded at $241.07, up about 5.71% over 24 hours. The move comes before detailed Phase 3 results for intismeran autogene, the personalized mRNA cancer therapy Moderna is developing with Merck, are scheduled to be presented at the European Society for Medical Oncology meeting on Oct. 24 at 22:30 Beijing time, followed by an investor event at 01:00 on Oct. 25. The companies had said on Aug. 19 that the therapy in combination with Keytruda met the primary endpoint of recurrence-free survival and the key secondary endpoint of distant metastasis-free survival. TradingBeats data also showed a whale address beginning with 0x4e23 holding a roughly $4.518 million 10x isolated short in MRNA on Hyperliquid, with an estimated liquidation price of $248.37.

Moderna (MRNA) has rebounded ahead of a key cancer therapy data release. Over the last two U.S. trading sessions, the stock gained 4.07% and 6.69%, bringing the combined advance to about 11.04%. It last closed at $242.08 and reached an intraday high of $243.98. On Hyperliquid, the corresponding contract traded at $241.07, up about 5.71% over the past 24 hours.

Phase 3 readout set for ESMO

A major catalyst behind the move is the upcoming detailed Phase 3 data release for intismeran autogene, the personalized mRNA cancer therapy being developed jointly by Moderna and Merck. According to the company schedule, the two firms will present results from the INTerpath-001 Phase 3 study in high-risk melanoma at the European Society for Medical Oncology, or ESMO, meeting at 22:30 Beijing time on Oct. 24. An investor event is scheduled for 01:00 on Oct. 25.

The presentation is being watched as a detailed follow-up to previously announced positive results. On Aug. 19, the companies said the therapy in combination with Keytruda met the primary endpoint of recurrence-free survival, or RFS, and the key secondary endpoint of distant metastasis-free survival, or DMFS. Investors are expected to focus this weekend on the size of the benefit, the safety profile, and what the data may indicate for development in other cancers.

Stock has already priced in strong expectations

Since Aug. 18, the close of the trading session before those positive results were announced, MRNA has climbed about 284.5%. The share price has already reflected strong optimism around the company’s cancer pipeline. Even with the broader biotech sector performing well, MRNA still fell 7.82% in a single session last Friday, and the rebound over the past two sessions also marks a recovery from that pullback.

Wall Street firms have continued to raise valuation targets, though they have not moved in lockstep to chase the rally. Bank of America recently lifted its price target on Moderna to $220 from $200 and kept a neutral rating. The bank said the key focus at ESMO will be the actual magnitude of benefit from the combination therapy and whether the results can serve as a reference point for later studies in kidney cancer, bladder cancer, and other indications. Even after the increase, the $220 target remains about 9.1% below Moderna’s latest closing price of $242.08.

Whale short approaches liquidation

As the stock continues to trade near recent highs, a whale holding a short position worth about $4.52 million is nearing liquidation. According to TradingBeats monitoring, an address beginning with 0x4e23 is currently short about 18,700 MRNA contracts with 10x isolated leverage. The position is valued at about $4.518 million, with an average entry price of $237.04 and an unrealized loss of about $75,500.

The estimated liquidation price is $248.37, only about 3.03% above the current mark price, a gap of roughly $7.30. The trader also has three standard limit buy orders resting between $235.48 and $236.48, totaling about 3,522.98 contracts, or about $831,900, in an apparent attempt to exit around breakeven.

This article was originally published by Bit.Fan. For more cryptocurrency news and market insights, visit www.bit.fan.
12000

Disclaimer:

The market information, project data, and third-party content displayed on this platform are for industry information sharing only and do not constitute any form of investment advice or return commitment.

Cryptocurrency trading carries high risks. Users should fully assess their risk tolerance and make independent decisions. All profits, losses, and legal responsibilities are borne by the users themselves.

Moderna jumps 11% in two sessions as whale short nears liquidation before cancer data release | Bit.Fan